Document is current
Any future updates will be listed below
-
Authors
Muhar, Matthias F. https://orcid.org/0000-0002-3018-9698
Farnung, Jakob https://orcid.org/0000-0002-4619-3421
Cernakova, Martina https://orcid.org/0000-0002-6319-5082
Hofmann, Raphael https://orcid.org/0000-0002-9769-6555
Henneberg, Lukas T. https://orcid.org/0000-0003-3477-4541
Pfleiderer, Moritz M. https://orcid.org/0000-0002-2369-5824
Denoth-Lippuner, Annina https://orcid.org/0000-0003-0357-5208
Kalčic, Filip https://orcid.org/0000-0002-4391-8319
Nievergelt, Ajse S.
Peters Al-Bayati, Marwa
Sidiropoulos, Nikolaos D. https://orcid.org/0000-0003-3257-3455
Beier, Viola
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Jessberger, Sebastian https://orcid.org/0000-0002-0056-8275
Jinek, Martin https://orcid.org/0000-0002-7601-210X
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Bode, Jeffrey W. https://orcid.org/0000-0001-8394-8910
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
- License Information
-
More Information
Article History
Received: 14 June 2023
Accepted: 2 December 2024
First Online: 29 January 2025
Change Date: 2 May 2025
Change Type: Update
Change Details: In the version of the article initially published, in Extended Data Fig. 7e and f, the first, fifth and ninth x-axis labels originally read “−/+” and have now been corrected to “−/−” in the HTML and PDF versions of the article.
Competing interests
: M.F.M., J.F., R.H., J.W.B. and J.E.C. have filed patent applications related to MAAD discovery and mechanisms of FBXO31 substrate recognition performed in this study (WO/2024/115740, WO/2024/115746; both pending). J.W.B. and J.E.C. are founders of and M.F.M. and J.F. provide consultancy to Serac Biosciences. J.E.C. serves on the scientific advisory board of Mission Therapeutics. B.A.S. serves on the scientific advisory boards of Biotheryx and Proxygen. M.M. is an indirect investor of the Evosep company. The other authors declare no competing interests.
